Meghan Bowler, PhD

Meghan Bowler, PhD

Translational Scientist

Dr. Bowler is a Biomedical Engineer whose research career has been characterized by an interest in how cells communicate. During her undergraduate studies at Stanford University, Dr. Bowler performed research in immunology and molecular biology at the Stanford Center for Clinical Sciences Research and the Berlin-Brandenburg Center for Regenerative Therapies in Germany. Her doctoral work at Vanderbilt University, partially funded by an NSF GRFP fellowship, focused on a cell-cell adhesion protein, cadherin-11, integral to the pathogenesis of calcific aortic valve disease. In the pursuit of novel targeting strategies for aortic valve calcification, Dr. Bowler discovered an unanticipated effect of celecoxib, a “heart-safe” NSAID, in promoting calcification in vitro that was supported by a retrospective analysis of electronic medical records. This publication received the most attention (highest Altmetric score) of any paper from that journal in 2019.

At FirstString Research, Dr. Bowler is able to move translational research from the bench to the bedside in the field of intercellular signaling. Her role is to design and coordinate preclinical and clinical studies for grant applications and oversee their implementation with partnering institutions, whether that be a CRO or an academic group. Throughout her prior positions and at FirstString, Dr. Bowler has demonstrated an ability to manage multiple projects simultaneously, coordinate with various stakeholders, and provide the scientific expertise necessary for success. She is enthusiastic about and committed to connecting innovative research and cutting-edge therapeutics with individuals who have unmet medical needs.